TG Therapeutics, Inc.

US$59.83As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:TGTXHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR 27.24%
Div yield —
ROE 100.28%
Biotechnology
Beta (5Y) 1.81
PE TTM 21.61
TSR TTM 72.01%
Mkt cap US$8.486B
ROIC 16.74%
SE Grade™
Value
Quality
Moat
Consensus
Reference
$72
20.78%
207.76%
Hold 2|9|6|12|9
4Q25
1Q26
2Q26
3Q26
Earnings per share$
1.30
1.42
1.39
1.50
40.80%
42.18%
28.23%
27.87%
Revenue$M
427.4
433.2
453.0
475.2
(0.35%)
0.34%
5.92%
9.99%
Peers (US$8.486B)
Cap (US$)
PE
8.916B
40.87x
Capital
TTM
5Y
10Y
Leveragex
1.915
—
—
EBIT/Intx
1.469
4.538
3.945
Own earn%
(56.16)
(91.38)
(62.85)
Sh yield%
50.82
29.47
25.49
Owners
Insiders/Inst%
5.93
21.42
Short interest%
4.49
SBC / revenue%
3.45
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
2
Op margin range%
0–2
$1 testx
0.0
Incr. ROIC%
18